There was no change even after they adjusted.

There was no change even after they adjusted, if possible, to take into account socio-economic status and co – exisiting illnesses. MS to delay conclusions about the use of interferon beta progress Shirani and colleagues conclude:.

But they explain , there are not enough studies to follow the effects of interferon beta to patients in the long run.

The follow-up period differed between the groups. It was much more for the historical untreated group . The median follow-up time for contemporary groups was 5.1 years for treated patients with MS and 4.0 years for the untreated MS patients. Continue reading

Page 5 of 512345